Gilead Sciences, Inc. which can be found using ticker (GILD) have now 24 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $106.98 and $63.63 suggesting an average analyst share price target price of $82.15. (at the time of writing). Now with the previous closing price of $79.07 this would imply there is now a potential upside of 3.9%. Also worth taking note is the 50 day moving average now sits at $80.22 while the 200 day moving average is $78.46. The total market capitalization for the company now stands at 98.52B. The stock price for the company is currently $78.62 USD
The potential market cap would be $102,362,031,121 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 16.84, revenue per share of $21.90 and a 9.21% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
